IRENE

Amended Notice of Pendency and Proposed Settlement of Class Action Involving Record and Beneficial Holders of Ameritrade Common Stock During the Period From and Including November 25, 2019 Through and Including October 6, 2020

Retrieved on: 
Monday, August 8, 2022

Certain persons and entities are excluded from the Settlement Class by definition, as set forth in the full Amended Notice of Pendency and Proposed Settlement of Stockholder Class Action, Settlement Hearing, and Right to Appear(the "Amended Notice"), available at www.AmeritradeMergerLitigation.com .

Key Points: 
  • Certain persons and entities are excluded from the Settlement Class by definition, as set forth in the full Amended Notice of Pendency and Proposed Settlement of Stockholder Class Action, Settlement Hearing, and Right to Appear(the "Amended Notice"), available at www.AmeritradeMergerLitigation.com .
  • YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • Please do not contact the Court or the Office of the Register in Chancery regarding this Amended Summary Notice.
  • All questions about this Amended Summary Notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Settlement Administrator or Plaintiff's Co-Lead Counsel.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, March 3, 2022

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.
  • Dr. Coffey continued, "Our efforts to advance towards our 2022 milestones are built upon the progress we made in 2021.
  • The net loss for the fourth quarter of 2021 was $7.8 million, compared to a net loss of $9.3 million in the fourth quarter of 2020.
  • The basic and diluted loss per share was $0.14 in the fourth quarter of 2021, compared to a basic and diluted loss per share of $0.21 in the fourth quarter of 2020.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, March 3, 2022

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.
  • Dr. Coffey continued, "Our efforts to advance towards our 2022 milestones are built upon the progress we made in 2021.
  • The net loss for the fourth quarter of 2021 was $7.8 million, compared to a net loss of $9.3 million in the fourth quarter of 2020.
  • The basic and diluted loss per share was $0.14 in the fourth quarter of 2021, compared to a basic and diluted loss per share of $0.21 in the fourth quarter of 2020.

Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential

Retrieved on: 
Monday, January 24, 2022

According to Precedence Research , the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030.

Key Points: 
  • According to Precedence Research , the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030.
  • Among the up-and-coming treatments that made significant advancements in 2021 was pelareorep, the flagship immunotherapeutic agent of Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).
  • According to the company's official pipeline , multiple studies are being conducted to test pelareorep in combination with some of the sector's highest-selling cancer drugs to treat various forms of cancer, including breast cancer, gastro-intestinal cancer, and multiple myeloma.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential

Retrieved on: 
Monday, January 24, 2022

VANCOUVER, BC, Jan. 24, 2022 /PRNewswire/ -- USA News Group  -  Within the grand battle against cancer, the use of immunotherapy continues to grow at incredible rates. According to Precedence Research, the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030. According to Johns Hopkins Medicine, precision medicine is at the heart of immunotherapy, however a recent survey of precision oncology programs showed that the rapid pace of advances have caused a major challenge for oncologists. Momentum in the immunotherapy segment continues to draw plenty of investment and interest into the work of developers, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exact Sciences Corporation (NASDAQ:EXAS), Sanofi (NASDAQ:SNY), Novartis AG (NYSE:NVS) and BeiGene, Ltd. (NASDAQ:BGNE).

Key Points: 
  • According to Precedence Research , the global cancer immunotherapy market is set to grow at a CAGR of 12.6% to a whopping $277.1 billion by 2030.
  • Among the up-and-coming treatments that made significant advancements in 2021 was pelareorep, the flagship immunotherapeutic agent of Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).
  • According to the company's official pipeline , multiple studies are being conducted to test pelareorep in combination with some of the sector's highest-selling cancer drugs to treat various forms of cancer, including breast cancer, gastro-intestinal cancer, and multiple myeloma.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

Retrieved on: 
Friday, January 14, 2022

Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.

Key Points: 
  • Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.
  • According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%.
  • Within its Breast Cancer Program so far, Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213as seen from study results delivered in 2017.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

Retrieved on: 
Friday, January 14, 2022

VANCOUVER, BC, Jan. 14, 2022 /PRNewswire/ -- USA News Group - Cancer cases are on the rise, according to a new study comparing the number of cancer diagnoses globally in 2010 and 2019. Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019. According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%. Among the biotech developers working into 2022 on new treatments for breast cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Roche Holding AG (OTC:RHHBY), Pfizer Inc. (NYSE:PFE), Incyte Corporation (NASDAQ:INCY) and AstraZeneca PLC (NASDAQ:AZN).

Key Points: 
  • Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.
  • According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%.
  • Within its Breast Cancer Program so far, Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213as seen from study results delivered in 2017.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Promising Developments in Breast Cancer Treatments Ahead in 2022

Retrieved on: 
Wednesday, January 12, 2022

VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ -- USA News Group - So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a decade long analysis .

Key Points: 
  • VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ -- USA News Group - So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a decade long analysis .
  • There are plenty more developments to come from biotech companies working into 2022 on new treatments for breast cancer including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Illumina, Inc. (NASDAQ:ILMN), Zai Lab Limited (NASDAQ:ZLAB), Merus N.V. (NASDAQ:MRUS), and Veru Inc.(NASDAQ:VERU).
  • For breast cancer patients treated with pelareorep Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- in IND-213as seen from study results delivered in 2017.
  • We are excited to see this potential new treatment option for patients living with metastatic breast cancer in China."

Promising Developments in Breast Cancer Treatments Ahead in 2022

Retrieved on: 
Wednesday, January 12, 2022

VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ -- USA News Group - So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a decade long analysis .

Key Points: 
  • VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ -- USA News Group - So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a decade long analysis .
  • There are plenty more developments to come from biotech companies working into 2022 on new treatments for breast cancer including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Illumina, Inc. (NASDAQ:ILMN), Zai Lab Limited (NASDAQ:ZLAB), Merus N.V. (NASDAQ:MRUS), and Veru Inc.(NASDAQ:VERU).
  • For breast cancer patients treated with pelareorep Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- in IND-213as seen from study results delivered in 2017.
  • We are excited to see this potential new treatment option for patients living with metastatic breast cancer in China."

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks

Retrieved on: 
Wednesday, December 8, 2021

Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis .

Key Points: 
  • Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis .
  • "These milestones include the reporting of new clinical biomarker data from our AWARE-1 breast cancer study, which we are pleased to be announcing today.
  • It also indicates that changes in peripheral blood T cell populations may be predictive of patient response.
  • We look forward to working with her team in our advanced breast cancer clinical trial to accelerate patient recruitment."